Maria Garcia-Velloso

Dr. Maria Garcia-Velloso

SOCIETY OF NUCLEAR MEDICINE
+3
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
GFGema Frühbeck
Gema Frühbeck
SBSara Becerril
Sara Becerril
NSNeira Sáinz
Neira Sáinz
PGPuy Garrastachu
Puy Garrastachu
MGMaria Garcia-Velloso
Maria Garcia-Velloso

21 January 2009 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
AGA. Gil‐Rendo
A. Gil‐Rendo
FMF. Martínez‐Regueira
F. Martínez‐Regueira
GZG. Zornoza
G. Zornoza
MGMaria Garcia-Velloso
Maria Garcia-Velloso
CBC. Beorlegui
C. Beorlegui
NRN. Rodriguez‐Spiteri
N. Rodriguez‐Spiteri
Background: This study analysed the correlation between [18F]fluorodeoxyglucose (FDG) uptake assessed by positron emission tomography (PET) in breast tumours, and histopathological and inmunohistochemical prognostic factors. Methods: FDG–PET was performed before surgery in 275 women with primary breast cancer. The standarized uptake value (SUV) was compared with histopathological findings after surgery. Results: A positive relationship was found between the SUV and tumour size (r = 0·46, P < 0·001), axillary lymph node status (P < 0·001), histological type (P < 0·001), histological grade (P < 0·001), oestrogen receptor status (P < 0·001), p53 (P < 0·001) and Ki‐67 (P < 0·001) expression. Multivariable linear regression showed that tumour size, histological grade, Ki‐67 expression, oestrogen receptor status and histological type were significantly related to the SUV. Conclusion: The SUV is a preoperative and non‐invasive metabolic factor that relates to some prognostic factors in breast cancer. Copyright © 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

1 April 2006 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
JGJuan J. Gavira
Juan J. Gavira
JHJesús Herreros
Jesús Herreros
APAna Pérez
Ana Pérez
MGMaria Garcia-Velloso
Maria Garcia-Velloso
JBJoaquín Barba
Joaquín Barba
FPFelipe Prosper
Felipe Prosper

19 June 2009 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
JRJosé A. Richter
José A. Richter
MRMacarena Rodríguez
Macarena Rodríguez
JRJorge Rioja
Jorge Rioja
IPIvan Penuelas
Ivan Penuelas
JMJosep Martí-Climent
Josep Martí-Climent
MGMaria Garcia-Velloso
Maria Garcia-Velloso

3 July 2014 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
CCCarlos Caicedo
Carlos Caicedo
MGMaria Garcia-Velloso
Maria Garcia-Velloso
Maria D. EscarioMaria D. Escario
Maria D. Escario
TLTania Labiano
Tania Labiano
CDCarmen Vigil Diaz
Carmen Vigil Diaz
JGJose Luis Perez Gracia
Jose Luis Perez Gracia

24 April 2017 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
JMJosep M. Martí-Climent
Josep M. Martí-Climent
EPElena Prieto
Elena Prieto
VMVerónica Morán
Verónica Morán
LSLidia Sancho
Lidia Sancho
MRMacarena Rodríguez-Fraile
Macarena Rodríguez-Fraile
JRJosé A. Richter
José A. Richter
The aim of this study was to retrospectively evaluate the patient effective dose (ED) for different PET/CT procedures performed with a variety of PET radiopharmaceutical compounds. PET/CT studies of 210 patients were reviewed including Torso (n = 123), Whole body (WB) (n = 36), Head and Neck Tumor (HNT) (n = 10), and Brain (n = 41) protocols with 18FDG (n = 170), 11C-CHOL (n = 10), 18FDOPA (n = 10), 11C-MET (n = 10), and 18F-florbetapir (n = 10). ED was calculated using conversion factors applied to the radiotracer activity and to the CT dose-length product. Total ED (mean ± SD) for Torso-11C-CHOL, Torso-18FDG, WB-18FDG, and HNT-18FDG protocols were 13.5 ± 2.2, 16.5 ± 4.5, 20.0 ± 5.6, and 15.4 ± 2.8 mSv, respectively, where CT represented 77, 62, 69, and 63% of the protocol ED, respectively. For 18FDG, 18FDOPA, 11C-MET, and 18F-florbetapir brain PET/CT studies, ED values (mean ± SD) were 6.4 ± 0.6, 4.6 ± 0.4, 5.2 ± 0.5, and 9.1 ± 0.4 mSv, respectively, and the corresponding CT contributions were 11, 14, 23, and 26%, respectively. In 18FDG PET/CT, variations in scan length and arm position produced significant differences in CT ED (p < 0.01). For dual-time-point imaging, the CT ED (mean ± SD) for the delayed scan was 3.8 ± 1.5 mSv. The mean ED for body and brain PET/CT protocols with different radiopharmaceuticals ranged between 4.6 and 20.0 mSv. The major contributor to total ED for body protocols is CT, whereas for brain studies, it is the PET radiopharmaceutical.